

SUPPORTING DECENTRALIZED GENE THERAPY VISITS



Challenge

- Frequent yet simple sample collections can be burdensome and time consuming for many patients and disruptive to site personnel that are often consumed with larger responsibilities.
- Several enrolled patients were located in rural areas, making frequent visits to the site inconvenient and at times, impossible.
- Many key visits were often unscheduled, or unexpected, causing the patient to have to make last-minute travel arrangements to the site, interrupting both work and home life obligations.



Solution

- ProPharma Group's Decentralized Clinical Trial (DCT) team consulted with and proposed decentralized clinical visit (DCV) solutions to the sponsor for appropriate visits.
- ProPharma Group's team of GoClinical Clinicians were utilized to provide these decentralized visits. Given their active employed status, the clinicians successfully met study timelines, patient needs and expectations, even in last-minute situations.
- Our DCT team collaborated with the Sponsor to successfully operationalize DCV solutions. This allowed for our clinicians to be meticulously trained and provided with sample collection materials for safe and successful decentralized visits.



Results

- Rurally located patients remained eligible and enrolled by utilizing DCVs.
- ProPharma Group clinicians established and maintained professional relationships with patients for continued safe and efficient data collection.
- Non-traditional collections, such as stool collection, were done in the preferred and private location of the patient.
- Successful completion of over 100 unscheduled visits throughout the duration of the study.